Y-mAbs Therapeutics
Stock Forecast, Prediction & Price Target
Y-mAbs Therapeutics (YMAB) stock Price Target by analysts
$24
Potential upside: 181.35%
Y-mAbs Therapeutics price prediction
What is Y-mAbs Therapeutics stock analysts` prediction?
Y-mAbs Therapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Y-mAbs Therapeutics in the last 3 months, the avarage price target is $24, with a high forecast of $NaN. The average price target represents a 181.35% change from the last price of $8.53.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Y-mAbs Therapeutics stock Price Target by analysts
Full breakdown of analysts given Y-mAbs Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Etzer Darout BMO Capital | 0% 0/2 | 10 months ago | $24 181.35% upside | $15.06 | StreetInsider | Previous targets (1) |
Nicole Germino Truist Financial | 0% 0/1 | about 1 year ago | $21 146.18% upside | $12.33 | StreetInsider | Previous targets (0) |
Robert Burns H.C. Wainwright | 0% 0/1 | over 1 year ago | $22 157.91% upside | $12.87 | TheFly | Previous targets (0) |
Etzer Darout BMO Capital | 0% 0/2 | over 1 year ago | $26 204.80% upside | $14.56 | StreetInsider | Previous targets (1) |
YMAB)to Outperform Wedbush | 100% 1/1 | over 2 years ago | $13 52.40% upside | $9.9 | Benzinga | Previous targets (0) |
Etzer Darout Guggenheim | 0% 0/1 | almost 3 years ago | $18 111.01% upside | $4.73 | TheFly | Previous targets (0) |
William Maughan Telsey Advisory | 0% 0/1 | almost 3 years ago | $35 310.31% upside | $8.93 | TheFly | Previous targets (0) |
Y-mAbs Therapeutics Financial Estimates
Y-mAbs Therapeutics Revenue Estimates
Y-mAbs Therapeutics EBITDA Estimates
Y-mAbs Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $34.89M N/A | $65.26M 87.02% | $84.81M 29.95% | Avg: $116.91M Low: $109.95M High: $124.37M avg. 37.84% | Avg: $125.94M Low: $118.17M High: $134.45M avg. 7.72% | Avg: $142.10M Low: $133.34M High: $151.71M avg. 12.83% | Avg: $211.95M Low: $198.88M High: $226.27M avg. 49.14% |
Net Income
% change YoY
| $-56.34M N/A | $-96.32M -70.95% | $-21.42M 77.75% | Avg: $-29.54M Low: $-43.20M High: $-7.85M avg. -37.87% | Avg: $-63.96M Low: $-54.12M High: $-46.70M avg. -116.52% | Avg: $-45.68M Low: $-49.69M High: $-42.02M avg. 28.58% | Avg: $-14.18M Low: $-15.43M High: $-13.04M avg. 68.94% |
EBITDA
% change YoY
| $-115.43M N/A | $-94.81M 17.86% | $-25.67M 72.92% | Avg: $-52.40M Low: $-55.74M High: $-49.28M avg. -104.13% | Avg: $-56.45M Low: $-60.26M High: $-52.97M avg. -7.72% | Avg: $-63.69M Low: $-68.00M High: $-59.77M avg. -12.83% | Avg: $-95.00M Low: $-101.42M High: $-89.14M avg. -49.14% |
EPS
% change YoY
| -$1.3 N/A | -$2.2 -69.23% | -$0.49 77.72% | Avg: -$0.61 Low: -$0.99 High: -$0.18 avg. -24.08% | Avg: -$1.16 Low: -$1.24 High: -$1.07 avg. -90.78% | Avg: -$1.05 Low: -$1.14 High: -$0.96 avg. 9.76% | Avg: -$0.33 Low: -$0.35 High: -$0.3 avg. 68.94% |
Operating Expenses
% change YoY
| $147.81M N/A | $152.51M 3.17% | $99.07M -35.03% | Avg: $144.30M Low: $135.71M High: $153.50M avg. 45.65% | Avg: $155.44M Low: $145.86M High: $165.95M avg. 7.72% | Avg: $175.39M Low: $164.58M High: $187.25M avg. 12.83% | Avg: $261.59M Low: $245.46M High: $279.28M avg. 49.14% |
FAQ
What is Y-mAbs Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -14.21% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -43.20M, average is -29.54M and high is -7.85M.
What is Y-mAbs Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 26.88% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $109.95M, average is $116.91M and high is $124.37M.
What is Y-mAbs Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -9.03% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.99, average is -$0.61 and high is $-0.18.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Y-mAbs Therapeutics stock. The most successful analyst is Etzer Darout.